Enroll in a Study
Chronic Kidney Disease
Bayer
Protocol # 22040
Study Details
1 year
Patient Information
Are you 18 years of age or older with with Chronic Kidney Disease (CKD) & Albuminuria?
This study aims to evaluate the efficacy and safety of a new medication, lorundrostat, which we believe holds promise for improving the treatment of hypertension. By participating in this study, you will be contributing to the advancement of medical science.
Your involvement can help us evaluate the effectiveness and safety BAY 3283142 (Investigational Drug) potentially leading to improved treatment options for patients worldwide.
Throughout the study, you will receive high-quality medical care from our dedicated research team. This includes regular health assessments, monitoring, and support, ensuring that your well-being is closely observed and managed.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
Physician Information
Target population: Adult patients with Chronic Kidney Disease (CKD) & Albuminuria.
The problem: The progression of CKD, particularly related to albuminuria, and the need for more effective treatments to reduce albuminuria and slow kidney disease progression.
Why the problem exists: One of the key markers of CKD progression is albuminuria. Kidneys are not filtering protein properly.
New approach to solve the problem: Investigating the efficacy and safety of BAY 3283142 in reducing albuminuria when added to standard CKD care. The study will be randomized, placebo-controlled, and double-blind, with multiple doses of the drug being tested.
Study: A Phase 2b Study of BAY 3283142 in Chronic Kidney Disease Patients with Albuminuria
Study duration: 1 year
New intervention: BAY 3283142 (Investigational Drug)
Study purpose: To evaluate the efficacy and safety of BAY 3283142, an experimental drug, in reducing albuminuria in patients with CKD.
Sponsor Name: Bayer
PI(s): Dr. Jill Meyer & Dr. George Fadda
Revelation Biosciences Sub, Inc.
Protocol # RVL-CKD01
Study Details
1-3 months
Patient Information
Are you 18 years of age or older with Stage 3 or 4 Chronic Kidney Disease (CKD)?
Your involvement can help us evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose of an investigational drug in patients with Stage 3 or 4 Chronic Kidney Disease (CKD).
Throughout the study, you will receive high-quality medical care from our dedicated research team. This includes regular health assessments, monitoring, and support, ensuring that your well-being is closely observed and managed.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
Physician Information
Target population: Adults with stage 3 or 4 chronic kidney disease (CKD).
The problem: The progression of CKD and the limited treatment options to slow the disease's progression.
Why the problem exists: Chronic Kidney Disease in Stage 3 and 4 represents a critical stage where kidney function is severely impaired, but there are few effective treatment options to slow or halt progression. This gap in treatment leads to increased complications and a high risk of kidney failure, creating an urgent need for new, targeted therapies to improve patient outcomes and quality of life.
New approach to solve the problem: This is an early-stage clinical trial that focuses on evaluating the safety, tolerability, and pharmacokinetics of a drug. The study will evaluate a single ascending dose of the investigational drug in patients with stage 3 or 4 CKD.
Study: Phase 1b Study of Single Ascending Dose in Stage 3 or 4 CKD (PRIME Study)
Study duration: 1-3 months
New intervention: Drug not disclosed
Study purpose: To evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose of an investigational drug in patients with Stage 3 or 4 Chronic Kidney Disease (CKD)
Sponsor Name: Revelation Biosciences Sub, Inc.
PI(s): Dr. Adam Horeish & Dr. George Fadda
Sign Up Today
If you have questions about Balboa Research,
please complete the contact form or call
George Nilsson, Clinical Research Director.
George Nilsson
Clinical Research Director
(858) 810-8072